SCHEMBL16017066

SCHEMBL16017066

CCCCCCCC(=O)O[C@@H]1Cc2c(OCc3ccccc3)cc(C)cc2O[C@@H]1c1ccc(OCc2ccccc2)c(OCc2ccccc2)c1

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ XDH P47989 1/20 0.46
▸ STING1 Q86WV6 1/20 0.43
▸ ABCB1 P08183 7/20 0.42
▸ MEN1 O00255 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ CYP3A4 P08684 1/20 0.41
▸ MAPK1 P28482 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ PTPN1 P18031 1/20 0.39
▸ BCHE P06276 1/20 0.38
▸ HPSE Q9Y251 1/20 0.38
▸ GABRA1 P14867 1/20 0.37
▸ GABRB2 P47870 1/20 0.37
▸ PRKCA P17252 5/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16016991 0.86 ALDH1A1 (0.55) STING1ABCB1MEN1MAPTKMT2A
SCHEMBL14701476 0.82 ABCB1 (0.50) XDHABCB1MEN1MAPTKMT2A
SCHEMBL17523266 0.82 STING1 (0.45) STING1ABCB1MEN1MAPTKMT2A
SCHEMBL17358236 0.81 STING1 (0.42) STING1ABCB1MEN1MAPTKMT2A
SCHEMBL17358246 0.81 STING1 (0.42) STING1ABCB1MEN1MAPTKMT2A
SCHEMBL16016989 0.81 PDE4A (0.42) STING1ABCB1MEN1MAPTKMT2A
SCHEMBL17358245 0.81 STING1 (0.42) STING1ABCB1MEN1MAPTKMT2A
SCHEMBL13508129 0.81 STING1 (0.53) STING1ABCB1MEN1MAPTKMT2A
SCHEMBL15450265 0.80 STING1 (0.43) STING1ABCB1MEN1MAPTKMT2A
SCHEMBL15450261 0.80 STING1 (0.43) STING1ABCB1MEN1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9187448-B2 Flavonoid compounds CARDERO THERAPEUTICS, INC. (US) 2015-11-17 — — US disclosed
US-20140256741-A1 FLAVONOID COMPOUNDS CARDERO THERAPEUTICS, INC. (US) 2014-09-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140256741-A1 FLAVONOID COMPOUNDS FIS1, TFAM, MFN2 XDH 2095/4885STING1 2452/4885ABCB1 3737/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback